Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place and restriction of prescribing indications.
DILI is also a significant cause of morbidity and mortality in many patient populations. Due to its idiosyncratic nature, variable presentation and the vast number of potential causative drugs as well as herbal and dietary supplements, DILI is often diagnosed late in its course when patients have severe liver disease. DILI, including acute liver failure requiring liver transplantation, can happen anytime to anyone taking medications, even over the counter medications. Unfortunately, there are no tests to predict who is at risk nor to diagnose this problem. Read more
Significant advances in science are taking place, but translating them into clinical treatments for an array of human diseases is being hampered by public policies that are not aligned with the public good. That observation was articulated by Kenneth L. Davis, MD, President and Chief Executive Officer of The Mount Sinai Medical Center, during a discussion on “What’s Holding Back Medical Progress?,” one of three talks in which he participated at the ninth annual Aspen Ideas Festival, in Colorado, which ran from June 26 – July 2.
Mount Sinai’s Neuroscience Training Program offers predoctoral students an exciting and distinctive curriculum taught by a nationally and internationally recognized faculty, and a laboratory experience that builds on groundbreaking, cutting edge expertise in basic and translational neuroscience across a wide range of psychiatric and neurological disorders. A student’s training experience uniquely interfaces basic research within a clinical context by virtue of the close apposition of basic and clinical research and clinical treatment programs at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Hospital. Indeed, all graduate students take a class in clinical neuroscience where they meet patients with brain diseases.
Mount Sinai’s leadership in biomedical research and patient care, together with Rensselaer Polytechnic Institute’s expertise in engineering and invention prototyping, form the foundation for a new academic affiliation agreement between the two institutions. The agreement signals a new era of biomedical discovery and entrepreneurship for the Icahn School of Medicine at Mount Sinai and Rensselaer.
The partnership, commemorated at a signing ceremony on Wednesday, May 22, promotes collaboration in educational programs and research, with the ultimate goal of developing innovative diagnostic tools and treatments for patients around the world.
More than 700 attendees showed their support for children’s environmental health at The Mount Sinai Medical Center’s sixth annual Greening Our Children luncheon, held on Monday, May 20, at the Hyatt Regency Greenwich in Connecticut.
Proceeds from the event—which featured a guest appearance from actress and author Jessica Alba—will be used to support Mount Sinai’s Children’s Environmental Health Center (CEHC) and the Laboratory for Molecular Environmental Chemistry at Mount Sinai. The CEHC and laboratory are led by Philip J. Landrigan, MD, MSc, Dean for Global Health, the Ethel H. Wise Professor of Community Medicine, and Professor of Pediatrics; and Robert O. Wright, MD, Professor of Preventive Medicine, and Pediatrics, at Icahn School of Medicine at Mount Sinai.
Eric M. Mindich, a member of Mount Sinai’s Boards of Trustees, and his wife, Stacey Mindich, have provided a leadership gift to advance groundbreaking science to improve children’s health. In recognition of their generosity, Mount Sinai’s Child Health and Development Institute recently was renamed The Mindich Child Health and Development Institute (MCHDI).
“Eric and Stacey’s extraordinarily generous gift represents a critical step toward Mount Sinai’s goal of transforming children’s health,” says Kenneth L. Davis, MD, President and Chief Executive Officer of The Mount Sinai Medical Center.
The Icahn School of Medicine at Mount Sinai has begun rolling out a series of projects for investigators in basic, translational, and clinical research that will streamline the research administration structure and make it easier to initiate and submit protocols and compete for funding.
“We are transforming and improving the research administration enterprise on behalf of our investigators,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. “This vital endeavor underscores our commitment to supporting innovative and highly competitive research that will lead to groundbreaking treatments for human diseases.”
Shutting down inflammation within the body, and then harnessing the immune system to recognize and destroy cancer cells, could provide the one-two punch needed to effectively treat head and neck cancers, according to researchers at Icahn School of Medicine at Mount Sinai.
Research into the pivotal role played by the inflammatory molecule inducible nitric oxide synthase (iNOS) in promoting cancer growth and immune evasion is being led by Andrew G. Sikora, MD, PhD, Assistant Professor and Director of Head and Neck Translational Research in the Department of Otolaryngology, Head and Neck Surgery.
In 2008, a first-year medical student named Jennifer Ling developed a program called the First Generation College Application Essay Writing and Scholarship Program, under the sponsorship of Students for Equal Opportunity in Medicine (SEOM). There were six students in the program, all of whom enrolled seeking help with their college application essays.
Three years later, Jennifer’s program merged with the Mount Sinai Scholars Program, a tutoring program originally sponsored by Mount Sinai’s Department of Health Education. The combined program was renamed the First Generation Scholars Program, and continues as an SEOM-sponsored program. Since then, the program has grown to include more than sixty students and mentors.
According to the CDC, all “Baby Boomers” should get tested for hepatitis C. This is based only on age and for this recommendation Baby Boomers are defined as those born between 1945 and 1965
Hepatitis C (HCV) is a viral infection of the liver that can lead to cirrhosis, liver cancer, liver transplant, and death. It has been found to be very common in this age group, and, as they age, the consequences of the infection can be more severe and be irreversible before there are any symptoms at all!
The CDC also recommends that people who test positive for HCV be counseled about alcohol intake and referred to a liver disease specialist, who is familiar with the treatments available. This is particularly important now for several reasons.